Pacira BioSciences, Inc. has unveiled significant findings from a real-world study assessing the impact of EXPAREL® (bupivacaine liposome injectable suspension) on opioid consumption and healthcare resource utilization following outpatient total hip arthroplasty in Medicare patients. Presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, the retrospective analysis utilized data from the Centers for Medicare & Medicaid Services, comparing EXPAREL’s effects to standard non-liposome bupivacaine treatments over a 12-month period.

The study demonstrated that patients receiving EXPAREL experienced substantial reductions in opioid use at all measured time points, with a decrease from 2,576 to 1,962 Morphine Milligram Equivalents (MMEs) over a year (P<0.0001). Additionally, healthcare utilization metrics showed that the EXPAREL group had significantly fewer inpatient admissions and emergency department visits, culminating in lower total medical costs—averaging $8,390 versus $9,250 in the non-LB group over the same period (P<0.0001). These findings highlight EXPAREL’s potential to mitigate opioid-related adverse events and reduce the economic burden associated with postoperative care.

The implications of these results are profound for the field of pain management and surgical recovery. As the healthcare landscape increasingly prioritizes non-opioid alternatives to combat the opioid crisis, EXPAREL’s demonstrated efficacy in reducing both opioid use and healthcare costs positions it as a valuable tool in postoperative pain management. This may shift research paradigms towards further exploration of liposomal formulations in pain therapies, potentially accelerating the development timelines for similar non-opioid treatments in various surgical settings.

Source: globenewswire.com